ArticleMMWR. Morbidity and mortality weekly report2022
Summary of Guidance for Minimizing the Impact of COVID-19 on Individual Persons, Communities, and Health Care Systems - United States, August 2022.
Article in MMWR. Morbidity and mortality weekly report, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Trial
- Factors Associated with COVID-19 Testing in Structurally Vulnerable Populations: An Exploratory Study in Southern Maine.Journal of Maine Medical Center · 2026Article
- Comparison of surgical site infection in pediatric patients using NSQIP-P data during COVID-19 pandemic and non-pandemic periods.Pediatric surgery international · 2025Article
- Perspectives on COVID-19 Vaccination Among Unvaccinated and Under-Vaccinated African American/Black and Latine Frontline Essential Workers: A Qualitative Exploration.AIDS and behavior · 2025Article
- Retrospective evaluation of measures in the field of occupational health services during the COVID-19 epidemic.Central European journal of public health · 2025Article
- Article
- The use of digital platforms and physical activity practice in a population from southern Brazil: Findings from the PAMPA Cohort.Preventive medicine reports · 2024Article
- Too Many Deaths, Too Many Left Behind: A People's External Review of the U.S. Centers for Disease Control and Prevention's COVID-19 Pandemic Response.AJPM focus · 2024Article
- Social distancing stress, anxiety/depression, COVID-19 diagnosis, gender identity, and immigration status.Archives of public health = Archives belges de sante publique · 2024Article
- Article
- Effectiveness of Vaccines and Antiviral Drugs in Preventing Severe and Fatal COVID-19, Hong Kong.Emerging infectious diseases · 2024Article
- Sustaining Functionality of Not-for-Profit Health Organisations During Pandemics: Lessons and COVID 19 Experience from Makerere University Walter Reed Project.The East African health research journal · 2024Article
- Assessing service usage and protective factors in a pediatric psychiatry clinic during the COVID-19 pandemic.Frontiers in psychology · 2024Article
- The Impact of Effective Vaccination on Clinical and Radiological Involvement in COVID-19 Patients.Medeniyet medical journal · 2023Article
- Changing social contact patterns among US workers during the COVID-19 pandemic: April 2020 to December 2021.Epidemics · 2023Article
- Association Between Hypertension and Diabetes Control and COVID-19 Severity: National Patient-Centered Clinical Research Network, United States, March 2020 to February 2022.Journal of the American Heart Association · 2023Article
- Dynamic Contact Networks of Residents of an Urban Jail in the Era of SARS-CoV-2.medRxiv : the preprint server for health sciences · 2023Article
- SARS-CoV-2 vaccination and infection in ozanimod-treated participants with relapsing multiple sclerosis.Annals of clinical and translational neurology · 2023Article
- Predictors of the post-COVID condition following mild SARS-CoV-2 infection.Nature communications · 2023Article
- Vaccination Status and Trends in Adult Coronavirus Disease 2019-Associated Hospitalizations by Race and Ethnicity: March 2020-August 2022.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As SARS-CoV-2, the virus that causes COVID-19, continues to circulate globally, high levels of vaccine- and infection-induced immunity and the availability of effective treatments and prevention tools have substantially reduced the risk for medically significant COVID-19 illness (severe acute illness and post-COVID-19 conditions) and associated hospitalization and death (1). These circumstances now allow public health efforts to minimize the individual and societal health impacts of COVID-19 by focusing on sustainable measures to further reduce medically significant illness as well as to minimize strain on the health care system, while reducing barriers to social, educational, and economic activity (2). Individual risk for medically significant COVID-19 depends on a person's risk for exposure to SARS-CoV-2 and their risk for developing severe illness if infected (3). Exposure risk can be mitigated through nonpharmaceutical interventions, including improving ventilation, use of masks or respirators indoors, and testing (4). The risk for medically significant illness increases with age, disability status, and underlying medical conditions but is considerably reduced by immunity derived from vaccination, previous infection, or both, as well as timely access to effective biomedical prevention measures and treatments (3,5). CDC's public health recommendations change in response to evolving science, the availability of biomedical and public health tools, and changes in context, such as levels of immunity in the population and currently circulating variants. CDC recommends a strategic approach to minimizing the impact of COVID-19 on health and society that relies on vaccination and therapeutics to prevent severe illness; use of multicomponent prevention measures where feasible; and particular emphasis on protecting persons at high risk for severe illness. Efforts to expand access to vaccination and therapeutics, including the use of preexposure prophylaxis for persons who are immunocompromised, antiviral agents, and therapeutic monoclonal antibodies, should be intensified to reduce the risk for medically significant illness and death. Efforts to protect persons at high risk for severe illness must ensure that all persons have access to information to understand their individual risk, as well as efficient and equitable access to vaccination, therapeutics, testing, and other prevention measures. Current priorities for preventing medically significant illness should focus on ensuring that persons 1) understand their risk, 2) take steps to protect themselves and others through vaccines, therapeutics, and nonpharmaceutical interventions when needed, 3) receive testing and wear masks if they have been exposed, and 4) receive testing if they are symptomatic, and isolate for ≥5 days if they are infected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.